Feeds:
Posts
Comments

Archive for May, 2018

5G technology will revive a global smartphone market that’s had near standstill growth for two years- by Prachi Bhardwaj – Business Insider

Posted in Uncategorized, tagged , , on May 31, 2018| Leave a Comment »

The smartphone market’s growth has been at a near standstill for two years and is expected to experience more of the same in 2018; however, it could be revived by the arrival of 5G in late 2019.

As this chart from Statista shows, the largest spike the global market experienced in the last decade was in 2010, when the number of smartphone shipments went up 75% from 173.5 million units in 2009. Since then, the smartphone market has grown by progressively smaller increments, until 2016 when it only grew by 2.5%.

Last year, the smartphone market actually shrank (-0.1%) for the first time, and estimates from International Data Corporation (IDC) show the market research firm expects more of the same this year.

Next year, however, the data shows things will change for the smartphone market: The introduction of 5G, the next generation wireless technology, will drive more and more growth, and in 2022 the year-over-year change could be back to 2016 levels.

Chart of the day Shayanne Gal/Business Insider

Read Full Post »

Churchill – He had a way with Words – the best

Posted in Uncategorized, tagged on May 29, 2018| Leave a Comment »

He had a

way with

words !!!

 

Read Full Post »

Memorial Day – May, 2019 -Remembering those who SERVED – pls see Gene Simmons Military Tribute- a MUST —May God Bless and Protect our Troops

Posted in Uncategorized, tagged on May 25, 2018| Leave a Comment »

May God Bless and Protect our Troops.

Please always remember “Freedom is NOT Free”

With “Thanks, Gratitude & Respect”

Read Full Post »

Silicon Valley Venture Capital Survey – First Quarter 2018 by Cynthia Clarfield Hess, Mark A. Leahy and Khang Tran

Posted in Uncategorized, tagged , , , , on May 24, 2018| Leave a Comment »

Silicon Valley Venture Capital Survey – First Quarter 2018

Full Analysis

By Cynthia Clarfield Hess, Mark A. Leahy and Khang Tran   •   May 24, 2018

Download the full report.

Background

This report analyzes the terms of 200 venture financings closed in the first quarter of 2018 by companies headquartered in Silicon Valley.

Overview of Results

Valuation Results Remain Strong but Have Flattened
Valuation results were generally flat in Q1 2018 compared to the prior quarter. Overall, valuation metrics are well above historical averages, but have plateaued since Q3 2017. Up rounds exceeded down rounds 75% to 15%, with 10% flat in Q1 2018, an increase from Q4 2017 when up rounds exceeded down rounds 70% to 19%, with 11% flat.

The Fenwick & West Venture Capital Barometer™ showed an average price increase in Q1 2018 of 74%, which was flat compared to the prior quarter. The average price increase had previously peaked in Q3 2017 after five consecutive quarters of increases before decreasing moderately in Q4 2017.

The median price increase of financings in Q1 2018 was 41%, a slight decrease from the 42% recorded in Q4 2017, and the second consecutive quarter of declines following four quarters of increases.

Internet/Digital Media Continues to Score Highest Valuation Results
Similar to the prior quarter, the internet/digital media industry recorded the strongest valuation results in Q1 2018 compared to the other industries, with an average price increase of 101% and a median price increase of 59%. However, the valuation results for the internet/digital media industry were moderately weaker compared to the prior quarter.

In contrast, the software, hardware and life sciences industries all recorded stronger valuation results in Q1 compared to the prior quarter. The hardware industry, in particular, recorded the second strongest valuation results in Q1 and the greatest improvement in valuation results compared to the prior quarter, with the average price increase increasing from 40% in Q4 2017 to 97% in Q1 2018 and the median price increase increasing from 13% in Q4 2017 to 52% in Q1 2018.

Download the full report covering top line trends for venture capital financings of Silicon Valley companies in Q1. ​​​​​​

Read Full Post »

May 2017 – Gerbsman Partners – Maximizing Intellectual Property & Enterprise Value for Medical Device and Life Science Companies

Posted in Uncategorized, tagged , , on May 23, 2018| Leave a Comment »

Good Afternoon
The objective of this email is to qualify any interest on your company may have in utilizing the services of Gerbsman Partners to help maximize and monetize value of Intellectual Property which the company would like to sell or license to others.
Gerbsman Partners has observed that some medical device and life science companies have developed or acquired through acquisition Intellectual Property, that are not being fully utilized and can generate considerable value.
Given such situations, the Gerbsman Partners team is available to discuss and develop plans and strategies that can lead to the goal of monetizing and maximizing value of this IP.
Gerbsman Partners focuses on maximizing enterprise value for stakeholders and shareholders in under-performing, under-capitalized and under-valued companies and their Intellectual Property, as well as maximizing value for Intellectual Property Patents & Processes.  Since 2001, Gerbsman Partners has been involved in maximizing value for 103 technology, medical device, life science, solar, fuel cell, cyber security, consumer and digital marketing companies and their Intellectual Property and has restructured/terminated over $810 million of real estate executory contracts and equipment lease/sub-debt obligations. Since inception in 1980, Gerbsman Partners has been involved in over $2.3 billion of financings, restructurings and M&A Transactions.
Gerbsman Partners has offices and strategic alliances in San Francisco, New York, McLean, VA/Washington DC, Orange County, Boston, Europe and Israel.
I look forward to speaking with you.

Best regards

Steve Gerbsman
Medial Device

Cardiovascular, Vascular, Endoscopy, Breast Imaging

  • Cardiomind Inc. – Stent delivery platform.
  • OmniSonics Medical Technologies Inc. – Vascular disease IP.
  • InnerPulse Inc. – Cardiac rhythm management (CRM) medical device company.
  • Myocor Inc. – Developing innovative cardiac reshaping devices to treat functional mitral regurgitation (FMR) and left ventricular (LV) dysfunction, both of which are significant in the progression of congestive heart failure (CHF).
  • NDO Surgical, Inc. – Flexible endoscopy technologies that enable surgical procedures through the body’s natural openings.
  • Viacor Inc. – Cardiac implant device for the treatment of functional mitral regurgitation.
  • XTENT Inc. – Customizable drug eluting stent systems for the treatment of cardiovascular disease.
  • GluMetrics, Inc. – Glucose monitoring medical device company
  • NeoGraft Technologies, Inc. – Acquired Vascular Patents from Kips Bay Medical
  • Palmaz Scientific, Inc. – Medical technology company
  • InterValve, Inc. – Medical devices for structural heart market
  • Gamma Medica – first fully digital, dual headed Molecular Breast Imaging (“MBI”) system

Spine

  • Applied Spine Technologies Inc. – Screw based dynamic stabilization system validated with Class 1 clinical data
  • AxioMed Spine, Corp. – Developed Freedom technology, with the goal of restoring spinal function to patients by adhering to the natural biomechanics of the spine.

Respiratory

  • Emphasis Medical Inc. – Endobronchial valves for the treatment of heterogeneous emphysema.
  • Uptake Medical, Inc. –  developing innovative, therapeutic bronchoscopic devices to treat advanced heterogeneous emphysema and lung cancer.

Orthopedics

  • NovaLign Orthopedic Inc. – Long bone fracture, intramedullary nail technology.

Opthomology

  • Optobionics – Retinal degeneration.
  • Refractec, Inc. – Radiofrequency (RF) device called ViewPoint CK System, used to perform NearVisionSM CK (Conductive Keratoplasty) treatment

Obesity

  • Satiety Inc. – Obesity product
Osteoperosis
     •   Tarsa Therapeutics –   Oral formulation contains recombinant salmon calcitonin – treatment pf postmenopausal osteoporosis

Life Science

  • Pluristem, Inc. – Stem cell research – Israel company
  • Igenica Biotherapeutics, Inc.. – harnessing the natural tumor microenvironment to deliver a pipeline of high-impact antibody-based cancer therapeutics
  • Pegasus Biologics Inc. – Developed and is commercializing a revolutionary bioscaffold comprised of highly organized collagen, sourced from equine pericardium that encourages the healing process by addressing the demands of a challenging biological environment.
  • Radiant Medical, Inc. – Endovascular therapeutic cooling.
  • Valentis, Inc. – Biotechnology company with small molecule, antibody, protein, gene and manufacturing assets.
  • Relypsa, Inc. – Acquisition of BioPharmaceutical Patents and Intellectual Property

 

 

 

Read Full Post »

Older Posts »